InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Grant Award to the University of Oxford to Conduct Anti-TNF Therapy Trial
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford were awarded a grant from the National Institute for Health and Care Research (“NIHR”) in the U.K. to conduct a feasibility trial. The trial will investigate whether anti-tumor necrosis factor (“TNF”) therapy, administered at the time of surgery, can reduce or prevent post operative…